




Section: [6. Anti-infective medicines](#) > [6.5. Antiprotozoal medicines](#) > [6.5.5. Antitrypanosomal medicines](#) > [6.5.5.1. African trypanosomiasis](#) > [6.5.5.1.1. Medicines for the treatment of 1st stage African trypanosomiasis](#)

EMLc
ATC codes: **P01CX02**

Indication	African trypanosomiasis <span>ICD11 code: <b>1F51</b></span>
INN	Suramin sodium
Medicine type	Chemical agent
List type	Core To be used for the treatment of the initial phase of Trypanosoma brucei rhodesiense infection.
Formulations	Parenteral > General injections > IV: 1 g in vial
EML status history	First added in 1977 ( <a href="#">TRS 615</a> ) Changed in 1979 ( <a href="#">TRS 641</a> ) Changed in 2007 ( <a href="#">TRS 946</a> ) Changed in 2007 ( <a href="#">TRS 950</a> )
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 
Wikipedia	<a href="#">Suramin sodium</a> 
DrugBank	<a href="#">Suramin sodium (Suramin)</a> 

## Summary of evidence and Expert Committee recommendations

The EMLc Subcommittee recommended that suramin sodium be endorsed for the EMLc for treatment of first-stage of Trypanosoma brucei rhodesiense infections. The Subcommittee noted that African trypanosomiasis is a major public health problem in affected countries. Medicines available for treating this infection are limited. Hence despite the toxicity profile, these medicines are still used. There is a paucity of documented information specific to children and recommendations for adults are usually followed.

